Zepp Health Corporation (NYSE:ZEPP) Q2 2023 Earnings Call Transcript

Page 2 of 2

Let’s put it in a different way from a OEM or ODM supplier type of a situation to a more a company which is – dependent on its own self-branded products whereby, we hope that we can come to a situation whereby our self-branded product sales is good enough to cover for our fixed cost to start with, right? And then I think the past six quarters, we have reported six quarters of losses. And then that was also part of the reason we are actually going through a so called transformation journey to go from a reliance on Xiaomi single big customer to Amazfit self-reliance, company as what our CEO just mentioned. So to assure you that where our relationship with Xiaomi is actually very strong, and it will continue to be strong, but we will do more and more risk return on investment type of analysis on the product categories we are cooperating with Xiaomi, right?

So we’ll set a very clear threshold on the gross margin, on the profitability of – which are bringing by the Xiaomi projects. And we’ll work with them on those projects, which also have a mutual benefit to our company because in the end, I have due responsible – responsibility towards our shareholders, right? So, I think that is on the Xiaomi partnership. And then with regard to your second question on whether or not we have any plans on the new partnerships other than Xiaomi. I think that is – there’s always plans from the company in the making, but I would not comment too much on this. I mean, if we were going to have or if there’s such a B2B relationship materializing, you will definitely hear from us in our IR website. And then I come back to your first question, which is on the overseas market performance.

I think put aside the Xiaomi revenues of the company, which is in the meantime, has been becoming a small portion of the company’s overall sales, on our self-branded products, it has always been having a different characteristics than – or a dependence on the Chinese sales we’re making in China, right? To – I think I’ve mentioned this many times in the previous calls, that majority of our self-branded products sales is actually coming from the so-called overseas markets or international markets the company has. The biggest part is coming out of Europe. And then, the second biggest part is coming out of Asia Pacific countries. And the third one is coming out of United States, and then with a small portion of that mix coming out of China. What we noticed in Q2 is that we’re actually growing in all these regions, except for China, and India whereby we also mentioned in our prepared remarks that we tapered from looking at the scale in these markets towards profitability.

So we first want to manage for profitability so that the overall company is positioned for a health profitability. And then we’re going to – as the next step, we’re going to look at whether or not we can actually make profitable growth to that – in that sequence. So – and if you look at our overseas markets, we see that U.S. market actually presents itself as a very lucrative and a growth potential market for us because we are well positioned in that market to compete with big brands like Garmin, Samsung and Fitbit. And we have this unique positioning that we have – the made in China manufacturing production capabilities in China, which we can address more the demand of the value segment. And in the meantime, we’re actually competing with Garmin on the high-end premium segment in the United States.

And then we think a year and a bit, I think our market share in – according to NPD, which is third-party market share research company, our market share according to them has come up from 0% to 10% or 11%, if I remember correctly. So I think that’s in a nutshell, our performance in the international markets and I hope that gives you a feeling for what it is.

Unidentified Analyst: Yes. That’s very helpful. Thank you, Leon.

Operator: As there are no further questions now, I’d like to turn the call back over to Grace Zhang for closing remarks.

Grace Zhang: Thank you once again for joining us today. If you have further questions, please feel free to contact Zepp’s Investor Relations department through the contact information provided on our IR website. This concludes this conference call. Thank you.

Operator: Again, this concludes the conference call. You may now disconnect your line. Thank you.

Follow Zepp Health Corporation (NYSE:ZEPP)

Page 2 of 2